CN107988255A - A kind of method of definite ATR and ERK calmodulin binding domain CaMs - Google Patents

A kind of method of definite ATR and ERK calmodulin binding domain CaMs Download PDF

Info

Publication number
CN107988255A
CN107988255A CN201710998559.1A CN201710998559A CN107988255A CN 107988255 A CN107988255 A CN 107988255A CN 201710998559 A CN201710998559 A CN 201710998559A CN 107988255 A CN107988255 A CN 107988255A
Authority
CN
China
Prior art keywords
atr
erk
atrip
binding domain
complexs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710998559.1A
Other languages
Chinese (zh)
Inventor
魏凤香
唐大木
何立智
万新红
裴元元
温丽娟
宿宁
尹爱华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Longgang District Maternal And Child Health Care Hospital
Original Assignee
Shenzhen Longgang District Maternal And Child Health Care Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Longgang District Maternal And Child Health Care Hospital filed Critical Shenzhen Longgang District Maternal And Child Health Care Hospital
Priority to CN201710998559.1A priority Critical patent/CN107988255A/en
Publication of CN107988255A publication Critical patent/CN107988255A/en
Priority to PCT/CN2018/117837 priority patent/WO2019076386A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a kind of method of definite ATR and ERK calmodulin binding domain CaMs, the beneficial effects of the present invention are：In the method for definite ATR provided by the invention and ERK calmodulin binding domain CaMs, pass through recombinant plasmid transfected cell, and using the method for co-immunoprecipitation, determine the zone of action of ERK kinases and ATR albumen, be conducive to further determine that function of these zones of action in DDR, so as to lay the first stone to further elucidate specific mechanism of action of the ERK kinases in DDR reactions, to further understanding the generation of tumour, the mechanism of action of antitumor drug, the rational use of medicines and finding new action target spot there is important theory significance and practical value.

Description

A kind of method of definite ATR and ERK calmodulin binding domain CaMs
Technical field
The present invention relates to technical field of molecular biology, the method for more particularly to a kind of definite ATR and ERK calmodulin binding domain CaMs.
Background technology
DNA damage reaction (DDR) is that eukaryotic safeguards the accuracy of hereditary information transmission and the important regulating and controlling of integrality Mechanism, is the important defense mechanism that human body resists malignant tumour.When DDR occurs, the protein kinase activation such as ATM, ATR simultaneously makes more Kind DNA damage prosecution protein phosphorylation is so as to start a series of signal transmission path.This seminar is studied recently finds ERK kinases ATM and ATR reaction DNA damage path in play important adjustment effect, co-immunoprecipitation it turns out that ERK kinases with ATR albumen is there are calmodulin binding domain CaM, but specific regulatory mechanism and binding site are not yet clear and definite.
The content of the invention
The technical problems to be solved by the invention are：A kind of method for providing definite ATR and ERK calmodulin binding domain CaMs, solves ERK The problem of calmodulin binding domain CaM between kinases and ATR albumen is not yet clear and definite.
In order to solve the above-mentioned technical problem, the technical solution adopted by the present invention is：A kind of definite ATR and ERK calmodulin binding domain CaMs Method, comprise the following steps：
S1：ERK is marked using HA；
S2：ATR is marked using Flag；
S3：First recombinant plasmid is built with the ATR of ERK and the Flag mark of HA marks；
S4：By the first Transfected Recombinant Plasmid of structure to 293T cells；
S5：Co-immunoprecipitation is carried out to the 293T cells after the first recombinant plasmid of transfection using the antibody of HA and Flag labels Experiment, obtains the first ATR-ATRIP complexs, and uses western blotting experiment detection co-immunoprecipitation experiment knots Fruit；
S6：Detection co-immunoprecipitation experiment is tested as a result, judging the kinases in ERK kinases according to western blotting Region or nonkinase region whether there is calmodulin binding domain CaM with ATR-ATRIP complexs；
S7：If ERK kinases, there are calmodulin binding domain CaM, positions the combination in ERK kinases and ATR with ATR-ATRIP complexs Domain；
S71：To knock out after the ATR of N-terminal marks with Flag, and the second recombinant plasmid built with the ERK of HA marks；
S72：To knock out after the ATR of FAT sequences marks with Flag, and the 3rd recombinant plasmid built with the ERK of HA marks；
S73：To knock out after the ATR of kinase region marks with Flag, and the 4th recombinant plasmid built with the ERK of HA marks；
S74：To knock out after the ATR of FATC sequences marks with Flag, and quintet plasmid built with the ERK of HA marks；
S8：Respectively by the second recombinant plasmid, the 3rd recombinant plasmid, the 4th recombinant plasmid, quintet plasmid transfection extremely 293T cells；
S9：Using the antibody of HA and Flag labels respectively to the 293T cells after the second recombinant plasmid of transfection, transfection the 3rd The 293T cells after 293T cells, the 4th recombinant plasmid of transfection, the 293T after transfection quintet plasmid after recombinant plasmid is thin Born of the same parents carry out co-immunoprecipitation experiment, obtain corresponding 2nd ATR-ATRIP complexs, the 3rd ATR-ATRIP complexs, the 4th ATR-ATRIP complexs, the 5th ATR-ATRIP complexs, and use western blotting experiment detection co-immunoprecipitations Experimental result；
S10：According to western blotting test detection co-immunoprecipitation experiment as a result, judge ERK kinases with accordingly The 2nd ATR-ATRIP complexs, the 3rd ATR-ATRIP complexs, the 4th ATR-ATRIP complexs or the 5th ATR-ATRIP Complex whether there is calmodulin binding domain CaM；
S11：If ERK and above-mentioned the 2nd ATR-ATRIP complexs of ATR-ATRIP calmodulin binding domain CaMs, the 3rd ATR-ATRIP are compound One of complex then may be used there are calmodulin binding domain CaM in body, the 4th ATR-ATRIP complexs or the 5th ATR-ATRIP complexs Determine the calmodulin binding domain CaM of ATR- and ERK.
The beneficial effects of the present invention are：Definite ATR provided by the invention is with the method for ERK calmodulin binding domain CaMs, passing through weight Group plasmid-transfected cells, and using the method for co-immunoprecipitation, determine the zone of action of ERK kinases and ATR albumen, be conducive into One step determines function of these zones of action in DDR, so as to further elucidate specific work of the ERK kinases in DDR reactions Laid the first stone with mechanism, to further understanding the generation of tumour, the mechanism of action of antitumor drug, the rational use of medicines and finding newly Action target spot has important theory significance and practical value.
Embodiment
For the technology contents that the present invention will be described in detail, the objects and the effects, it is explained below in conjunction with embodiment.
The design of most critical of the present invention is：The present invention uses co-immunoprecipitation by recombinant plasmid transfected cell Method, determines the zone of action of ERK kinases and ATR albumen.
The present invention relates to the method for a kind of definite ATR and ERK calmodulin binding domain CaMs, comprise the following steps：
S1：ERK is marked using HA；
S2：ATR, the ATR is marked to include ATR-kd using Flag；
S3：First recombinant plasmid is built with the ATR of ERK and the Flag mark of HA marks；
S4：By the first Transfected Recombinant Plasmid of structure to 293T cells；
S5：Co-immunoprecipitation is carried out to the 293T cells after the first recombinant plasmid of transfection using the antibody of HA and Flag labels Experiment, obtains the first ATR-ATRIP complexs, and uses western blotting experiment detection co-immunoprecipitation experiment knots Fruit；
S6：Detection co-immunoprecipitation experiment is tested as a result, judging ERK kinases and ATR- according to western blotting ATRIP complexs whether there is calmodulin binding domain CaM；
S7：If ERK kinases, there are calmodulin binding domain CaM, positions the combination in ERK kinases and ATR with ATR-ATRIP complexs Domain；
S71：To knock out after the ATR of N-terminal marks with Flag, and the second recombinant plasmid built with the ERK of HA marks；
S72：To knock out after the ATR of FAT sequences marks with Flag, and the 3rd recombinant plasmid built with the ERK of HA marks；
S73：To knock out after the ATR of kinase region marks with Flag, and the 4th recombinant plasmid built with the ERK of HA marks；
S74：To knock out after the ATR of FATC sequences marks with Flag, and quintet plasmid built with the ERK of HA marks；
S8：Respectively by the second recombinant plasmid, the 3rd recombinant plasmid, the 4th recombinant plasmid, quintet plasmid transfection extremely 293T cells；
S9：Using the antibody of HA and Flag labels respectively to the 293T cells after the second recombinant plasmid of transfection, transfection the 3rd The 293T cells after 293T cells, the 4th recombinant plasmid of transfection, the 293T after transfection quintet plasmid after recombinant plasmid is thin Born of the same parents carry out co-immunoprecipitation experiment, obtain corresponding 2nd ATR-ATRIP complexs, the 3rd ATR-ATRIP complexs, the 4th ATR-ATRIP complexs, the 5th ATR-ATRIP complexs, and use western blotting experiment detection co-immunoprecipitations Experimental result；
S10：According to western blotting test detection co-immunoprecipitation experiment as a result, judge ERK kinases with accordingly The 2nd ATR-ATRIP complexs, the 3rd ATR-ATRIP complexs, the 4th ATR-ATRIP complexs or the 5th ATR-ATRIP Complex whether there is calmodulin binding domain CaM；
S11：If ERK and above-mentioned the 2nd ATR-ATRIP complexs of ATR-ATRIP calmodulin binding domain CaMs, the 3rd ATR-ATRIP are compound One of complex then may be used there are calmodulin binding domain CaM in body, the 4th ATR-ATRIP complexs or the 5th ATR-ATRIP complexs Determine the calmodulin binding domain CaM of ATR- and ERK.
The beneficial effect of the method for above-mentioned definite ATR and ERK calmodulin binding domain CaMs is：The present invention is thin by Transfected Recombinant Plasmid Born of the same parents, and using the method for co-immunoprecipitation, determine the zone of action of ERK kinases and ATR albumen, be conducive to further determine that these Function of the zone of action in DDR, so as to lay base to further elucidate specific mechanism of action of the ERK kinases in DDR reactions Plinth, to further understanding the generation of tumour, the mechanism of action of antitumor drug, the rational use of medicines and finding new action target spot and have Important theory significance and practical value.
Further, above-mentioned definite ATR is with the method for ERK calmodulin binding domain CaMs, after the S11, further including step：
According to the calmodulin binding domain CaM of ATR and ERK, the interaction sites of the ATR and ERK are further determined that.
Further, in the method for above-mentioned definite ATR and ERK calmodulin binding domain CaMs, the S1 is specially：
S1：ERK, the ERK is marked to include ERK1/2 and ERK1/2-kd using HA.
Further, in the method for above-mentioned definite ATR and ERK calmodulin binding domain CaMs, the S2 is specially：
S2：ATR, the ATR is marked to include ATR-kd using Flag.
Further, in the method for above-mentioned definite ATR and ERK calmodulin binding domain CaMs, the S6 is specially：
S6：Detection co-immunoprecipitation experiment is tested as a result, judging the kinases in ERK kinases according to western blotting Region or nonkinase region whether there is calmodulin binding domain CaM with ATR-ATRIP complexs.
Embodiment 1
The method of a kind of definite ATR and ERK calmodulin binding domain CaMs, comprise the following steps：
S1：ERK1/2 and ERK1/2-kd is included using ERK described in HA marks ERK；
S2：ATR is marked using Flag；
S3：First recombinant plasmid is built with the ATR of ERK and the Flag mark of HA marks；
S4：By the first Transfected Recombinant Plasmid of structure to 293T cells；
S5：Co-immunoprecipitation is carried out to the 293T cells after the first recombinant plasmid of transfection using the antibody of HA and Flag labels Experiment, obtains the first ATR-ATRIP complexs, and uses western blotting experiment detection co-immunoprecipitation experiment knots Fruit；
S6：Detection co-immunoprecipitation experiment is tested as a result, judging ERK kinases and ATR- according to western blotting ATRIP complexs whether there is calmodulin binding domain CaM；
S7：If ERK kinases, there are calmodulin binding domain CaM, positions the combination in ERK kinases and ATR with ATR-ATRIP complexs Domain；
S71：To knock out after the ATR of N-terminal marks with Flag, and the second recombinant plasmid built with the ERK of HA marks；
S72：To knock out after the ATR of FAT sequences marks with Flag, and the 3rd recombinant plasmid built with the ERK of HA marks；
S73：To knock out after the ATR of kinase region marks with Flag, and the 4th recombinant plasmid built with the ERK of HA marks；
S74：To knock out after the ATR of FATC sequences marks with Flag, and quintet plasmid built with the ERK of HA marks；
S8：Respectively by the second recombinant plasmid, the 3rd recombinant plasmid, the 4th recombinant plasmid, quintet plasmid transfection extremely 293T cells；
S9：Using the antibody of HA and Flag labels respectively to the 293T cells after the second recombinant plasmid of transfection, transfection the 3rd The 293T cells after 293T cells, the 4th recombinant plasmid of transfection, the 293T after transfection quintet plasmid after recombinant plasmid is thin Born of the same parents carry out co-immunoprecipitation experiment, obtain corresponding 2nd ATR-ATRIP complexs, the 3rd ATR-ATRIP complexs, the 4th ATR-ATRIP complexs, the 5th ATR-ATRIP complexs, and use western blotting experiment detection co-immunoprecipitations Experimental result；
S10：According to western blotting test detection co-immunoprecipitation experiment as a result, judge ERK kinases with accordingly The 2nd ATR-ATRIP complexs, the 3rd ATR-ATRIP complexs, the 4th ATR-ATRIP complexs or the 5th ATR-ATRIP Complex whether there is calmodulin binding domain CaM；
S11：If ERK and above-mentioned the 2nd ATR-ATRIP complexs of ATR-ATRIP calmodulin binding domain CaMs, the 3rd ATR-ATRIP are compound One of complex then may be used there are calmodulin binding domain CaM in body, the 4th ATR-ATRIP complexs or the 5th ATR-ATRIP complexs Determine the calmodulin binding domain CaM of ATR- and ERK；
S12：According to the calmodulin binding domain CaM of ATR and ERK, the interaction sites of the ATR and ERK are further determined that.
In conclusion in the method for definite ATR provided by the invention and ERK calmodulin binding domain CaMs, it is thin by Transfected Recombinant Plasmid Born of the same parents, and using the method for co-immunoprecipitation, determine the zone of action of ERK kinases and ATR albumen, be conducive to further determine that these Function of the zone of action in DDR, so as to lay base to further elucidate specific mechanism of action of the ERK kinases in DDR reactions Plinth, to further understanding the generation of tumour, the mechanism of action of antitumor drug, the rational use of medicines and finding new action target spot and have Important theory significance and practical value.
Described is only the embodiment of the present invention, is not intended to limit the scope of the invention, every to be said using the present invention The equivalents that bright book content is made, are directly or indirectly used in relevant technical field, are similarly included in the present invention's In scope of patent protection.

Claims (5)

  1. A kind of 1. method of definite ATR and ERK calmodulin binding domain CaMs, it is characterised in that comprise the following steps：
    S1：ERK is marked using HA；
    S2：ATR is marked using Flag；
    S3：First recombinant plasmid is built with the ATR of ERK and the Flag mark of HA marks；
    S4：By the first Transfected Recombinant Plasmid of structure to 293T cells；
    S5：It is real that co-immunoprecipitation is carried out to the 293T cells after the first recombinant plasmid of transfection using the antibody of HA and Flag labels Test, obtain the first ATR-ATRIP complexs, and use western blotting experiment detection co-immunoprecipitation experiment results；
    S6：Detection co-immunoprecipitation experiment is tested as a result, judging ERK kinases and ATR-ATRIP according to western blotting Complex whether there is calmodulin binding domain CaM；
    S7：If ERK kinases is with ATR-ATRIP complexs, there are calmodulin binding domain CaM, positioning ERK kinases and the binding domain in ATR；
    S71：To knock out after the ATR of N-terminal marks with Flag, and the second recombinant plasmid built with the ERK of HA marks；
    S72：To knock out after the ATR of FAT sequences marks with Flag, and the 3rd recombinant plasmid built with the ERK of HA marks；
    S73：To knock out after the ATR of kinase region marks with Flag, and the 4th recombinant plasmid built with the ERK of HA marks；
    S74：To knock out after the ATR of FATC sequences marks with Flag, and quintet plasmid built with the ERK of HA marks；
    S8：It is respectively that the second recombinant plasmid, the 3rd recombinant plasmid, the 4th recombinant plasmid, quintet plasmid transfection is thin to 293T Born of the same parents；
    S9：Using the antibody of HA and Flag labels respectively to the 293T cells after the second recombinant plasmid of transfection, the restructuring of transfection the 3rd 293T cells after plasmid, the 293T cells after the 4th recombinant plasmid of transfection, the 293T cells after transfection quintet plasmid into Row co-immunoprecipitation experiment, obtains corresponding 2nd ATR-ATRIP complexs, the 3rd ATR-ATRIP complexs, the 4th ATR- ATRIP complexs, the 5th ATR-ATRIP complexs, and use western blotting experiment detection co-immunoprecipitation experiments As a result；
    S10：Detection co-immunoprecipitation experiment is tested according to western blotting as a result, judging ERK kinases and corresponding the Two ATR-ATRIP complexs, the 3rd ATR-ATRIP complexs, the 4th ATR-ATRIP complexs or the 5th ATR-ATRIP are compound Body whether there is calmodulin binding domain CaM；
    S11：If ERK and above-mentioned the 2nd ATR-ATRIP complexs of ATR-ATRIP calmodulin binding domain CaMs, the 3rd ATR-ATRIP complexs, One of complex then can determine that there are calmodulin binding domain CaM in 4th ATR-ATRIP complexs or the 5th ATR-ATRIP complexs The calmodulin binding domain CaM of ATR- and ERK.
  2. 2. the method for definite ATR according to claim 1 and ERK calmodulin binding domain CaMs, it is characterised in that after the S11, also wrap Include step：
    According to the calmodulin binding domain CaM of ATR and ERK, the interaction sites of the ATR and ERK are further determined that.
  3. 3. the method for definite ATR according to claim 1 and ERK calmodulin binding domain CaMs, it is characterised in that the S1 is specially：
    S1：ERK, the ERK is marked to include ERK1/2 and ERK1/2-kd using HA.
  4. 4. the method for definite ATR according to claim 1 and ERK calmodulin binding domain CaMs, it is characterised in that the S2 is specially：
    S2：ATR, the ATR is marked to include ATR-kd using Flag.
  5. 5. the method for definite ATR according to claim 3 and ERK calmodulin binding domain CaMs, it is characterised in that the S6 is specially：
    S6：Detection co-immunoprecipitation experiment is tested as a result, judging the kinase region in ERK kinases according to western blotting Or nonkinase region whether there is calmodulin binding domain CaM with ATR-ATRIP complexs.
CN201710998559.1A 2017-10-20 2017-10-20 A kind of method of definite ATR and ERK calmodulin binding domain CaMs Pending CN107988255A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710998559.1A CN107988255A (en) 2017-10-20 2017-10-20 A kind of method of definite ATR and ERK calmodulin binding domain CaMs
PCT/CN2018/117837 WO2019076386A1 (en) 2017-10-20 2018-11-28 Method for determining atr and erk binding region

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710998559.1A CN107988255A (en) 2017-10-20 2017-10-20 A kind of method of definite ATR and ERK calmodulin binding domain CaMs

Publications (1)

Publication Number Publication Date
CN107988255A true CN107988255A (en) 2018-05-04

Family

ID=62031014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710998559.1A Pending CN107988255A (en) 2017-10-20 2017-10-20 A kind of method of definite ATR and ERK calmodulin binding domain CaMs

Country Status (2)

Country Link
CN (1) CN107988255A (en)
WO (1) WO2019076386A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019076386A1 (en) * 2017-10-20 2019-04-25 深圳市龙岗区妇幼保健院 Method for determining atr and erk binding region

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258013A1 (en) * 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US8367349B2 (en) * 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2
CN107245502B (en) * 2017-06-14 2020-11-03 中国科学院武汉病毒研究所 CD 2-binding protein (CD2AP) and its interacting protein
CN107988255A (en) * 2017-10-20 2018-05-04 深圳市龙岗区妇幼保健院 A kind of method of definite ATR and ERK calmodulin binding domain CaMs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019076386A1 (en) * 2017-10-20 2019-04-25 深圳市龙岗区妇幼保健院 Method for determining atr and erk binding region

Also Published As

Publication number Publication date
WO2019076386A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
Kidger et al. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Shen et al. Trapping poly (ADP-ribose) polymerase
Ouyang et al. Discovery of a small-molecule bromodomain-containing protein 4 (BRD4) inhibitor that induces AMP-activated protein kinase-modulated autophagy-associated cell death in breast cancer
Torrisi et al. Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalization
Hou et al. Targeting Mnks for cancer therapy
Qiu et al. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter
D'Arcy et al. The antitumor drug LB-100 is a catalytic inhibitor of protein phosphatase 2A (PPP2CA) and 5 (PPP5C) coordinating with the active-site catalytic metals in PPP5C
He et al. Reversing multidrug resistance by tyrosine kinase inhibitors
Sabatel et al. Importance of PIKKs in NF-κB activation by genotoxic stress
Day et al. Phosphorylation-dependent assembly of DNA damage response systems and the central roles of TOPBP1
Kim et al. A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo
Chen et al. AKT mediates actinomycin D-induced p53 expression
Zhang et al. Hsp90 interacts with AMPK and mediates acetyl-CoA carboxylase phosphorylation
CN108137550A (en) To the mechanism of the resistance of BET bromine structural domain inhibitor
Yamaguchi et al. Structural insight into the ligand-receptor interaction between glycyrrhetinic acid (GA) and the high-mobility group protein B1 (HMGB1)-DNA complex
Merrouche et al. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells
Garibsingh et al. Homology modeling informs ligand discovery for the glutamine transporter ASCT2
Pommier et al. Novel clinical indenoisoquinoline topoisomerase I inhibitors: A twist around the camptothecins
CN107988255A (en) A kind of method of definite ATR and ERK calmodulin binding domain CaMs
Liao et al. CDK1 promotes nascent DNA synthesis and induces resistance of cancer cells to DNA-damaging therapeutic agents
Kaur et al. Chk1-dependent constitutive phosphorylation of BLM helicase at serine 646 decreases after DNA damage
Xu et al. Rab5a suppresses autophagy to promote drug resistance in cancer cells
Yang et al. Mitochondria‐associated endoplasmic reticulum membrane: Overview and inextricable link with cancer
Dong et al. Maslinic acid promotes autophagy by disrupting the interaction between Bcl2 and Beclin1 in rat pheochromocytoma PC12 cells
Schoenherr et al. Trafficking of adhesion and growth factor receptors and their effector kinases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180504

RJ01 Rejection of invention patent application after publication